RT Journal Article
T1 First-line treatment in lymphomatoid papulosis: a retrospective multicentre study.
A1 Fernández-de-Misa, R
A1 Hernández-Machín, B
A1 Servitje, O
A1 Valentí-Medina, F
A1 Maroñas-Jiménez, L
A1 Ortiz-Romero, P L
A1 Sánchez Schmidt, J
A1 Pujol, R M
A1 Gallardo, F
A1 Pau-Charles, I
A1 García Muret, M P
A1 Pérez Gala, S
A1 Román, C
A1 Cañueto, J
A1 Blanch Rius, L
A1 Izu, R
A1 Ortiz-Brugués, A
A1 Martí, R M
A1 Blanes, M
A1 Morillo, M
A1 Sánchez, P
A1 Peñate, Y
A1 Bastida, J
A1 Pérez Gil, A
A1 Lopez-Lerma, I
A1 Muniesa, C
A1 Estrach, T
AB Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce. To assess the daily clinical practice approach to LyP and the response to first-line treatments. This was a retrospective study enrolling 252 patients with LyP. Topical steroids, methotrexate and phototherapy were the most common first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively. Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time to CR was 10 months (95% CI 6-13 months), and 78% of complete responders showed cutaneous relapse; both results were similar for all treatment groups (P > 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P  0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P  Current epidemiological, clinical and pathological data support previous results. Topical steroids, phototherapy and methotrexate are the most frequently prescribed first-line treatments. Although CR and cutaneous relapse rates do not differ between them, phototherapy achieves a longer DFS. Presence of Type A LyP and use of topical steroid or methotrexate were associated with an increased risk of early relapse.
YR 2017
FD 2017-10-10
LK http://hdl.handle.net/10668/11661
UL http://hdl.handle.net/10668/11661
LA en
DS RISalud
RD Mar 13, 2025